IL6 and COVID-19: Of note, in DM patients with COVID-19, IL-6 links to associated metabolic disorders and cardiovascular complications, so IL-6 antagonist tocilizumab may attenuate the clinical course and outcomes in DM patients with COVID-19-induced pneumonia (48).